Cite
HARVARD Citation
Eggermont, A. et al. (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet oncology. 22 (5), pp. 643-654. [Online].